RxDoctor Payments DataLook up a doctor →

Noor Yono, MD

Clinical Neurophysiology · Stuart, FLNPI 1679896526

Payments from drug & device makers

$61,794in general payments, 2019–2025

Across 1,280 payments — averaging $48.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$28K
  • Biohaven Pharmaceuticals, Inc.$8K
  • Sunovion Pharmaceuticals Inc.$7K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Sanofi$1K
  • Biogen$1K
  • plus $14K from 54 others

What the payments were for

  • Consulting fees$1900%
  • Speaking & faculty fees$39,62764%
  • Travel & lodging$7461%
  • Food & beverage$21,07034%
  • Education$1610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)240$27,884
Biohaven Pharmaceuticals, Inc.18$8,285
Sunovion Pharmaceuticals Inc.47$6,561
Biohaven Pharmaceutical Holding Company Ltd.11$1,685
Sanofi42$1,416
Biogen60$1,340
Novartis100$1,327
UCB, Inc.44$1,050
AstraZeneca43$1,008
Zyla Life Sciences, Inc.102$756
Pfizer42$740
Acadia Pharmaceuticals Inc58$705
Argenx US, Inc.34$620
MDD US Operations, LLC33$545
Teva Pharmaceuticals USA, Inc.32$532
Kyowa Kirin, Inc.21$438
Eisai Inc.16$425
SK Life Science, Inc.16$352
Supernus Pharmaceuticals, Inc.20$346
Johnson & Johnson(2 entities)15$287
CSL Behring13$279
Aquestive Therapeutics, Inc.9$265
Genentech USA, Inc.13$260
Neurelis, Inc.15$254
EMD Serono, Inc.13$243
Jazz Pharmaceuticals Inc.14$237
Amgen(2 entities)10$224
Lundbeck LLC16$222
Lilly USA, LLC16$221
Bausch Health US, LLC13$218
Bristol Myers Squibb12$217
Tanabe Pharma America, Inc.12$212
Medtronic3$190
Impel Pharmaceuticals Inc.12$162
Greenwich Biosciences, Inc.7$155
Neurocrine Biosciences, Inc.9$153
Merz North America, Inc.6$149
Amneal Pharmaceuticals LLC9$141
Acorda Therapeutics, Inc6$130
Merz Pharmaceuticals, LLC5$123
Livanova USA, Inc.2$122
Grifols USA, LLC7$120
Upsher-smith Laboratories LLC8$114
GE HealthCare5$112
Avanir Pharmaceuticals, Inc.5$88
E.r. Squibb & Sons, L.L.C.4$85
Takeda Pharmaceuticals U.S.A., Inc.4$82
Alfasigma USA, Inc.3$64
Microtransponder, Inc.2$61
Arbor Pharmaceuticals, Inc.4$58
TG Therapeutics, Inc.2$51
Sumitomo Pharma America, Inc.3$50
Solta Medical, A Division Of Bausch Health US, LLC1$48
Octapharma USA, Inc.2$39
Avion Pharmaceuticals2$38
Assertio Therapeutics, Inc.5$38
Banner Life Sciences, LLC2$37
Promius Pharma LLC2$36
Otter Pharmaceuticals, LLC1$33
Aucta Pharmaceuticals, Inc.2$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$601,707
Medicare patients
1,166
Services billed
34,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5050$627,726
Kesimpta PenOfatumumab57$497,350
NuplazidPimavanserin Tartrate30$199,975
TecfideraDimethyl Fumarate13$120,814
IngrezzaValbenazine Tosylate12$97,179
BriviactBrivaracetam37$88,769
BotoxOnabotulinumtoxina43$53,280
EpidiolexCannabidiol (Cbd)12$41,944
Nurtec OdtRimegepant Sulfate23$41,544
AptiomEslicarbazepine Acetate26$33,490
NayzilamMidazolam20$32,859
UbrelvyUbrogepant15$22,889
Lacosamide161$20,407
Emgality PenGalcanezumab-Gnlm26$20,148
QuliptaAtogepant13$19,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$82$627,72650 claims
Acadia Pharmaceuticals IncNuplazid$705$199,97530 claims
UCB, Inc.Briviact, Nayzilam, Vimpat$1,050$134,54276 claims
BiogenTecfidera$1,340$120,81413 claims
AbbVieBotox, Ubrelvy, Qulipta, Namzaric$27,884$106,95483 claims
Neurocrine Biosciences, Inc.Ingrezza$153$97,17912 claims
PfizerNurtec Odt$740$41,54423 claims
Sunovion Pharmaceuticals Inc.Aptiom$6,561$33,49026 claims
Avanir Pharmaceuticals, Inc.Nuedexta$88$18,15311 claims
Amneal Pharmaceuticals LLCRytary$141$17,83111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Floridaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →